ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Draft FDA guidance on anti-infectives for children: It’s (mostly) all about PK and safety
What does an antibiotic cost to develop? What is it worth? How to afford it?
The hunt for oral antibiotics: Beyond Lipinski’s Rule of Five
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
FDA workshop: Insights on inhaled antifungals and antibacterials
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
FDA AMDAC – Developing Single-Pathogen agents for P. aeruginosa and A. baumannii
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet